Artificial Intelligence Models in Electrocardiogram Interpretation for Identification of Advanced Liver Disease

Overview

About this study

The purpose of this study is to evaluate the application of machine learning models, DULCE and ACE scores, in the identification of advanced liver fibrosis (stage 3-4) and clinically significant portal hypertension, respectivelly

The objectives of this study are to determine if the DULCE score can accurately predict advanced liver fibrosis (stage 3-4) using 6-lead and 12-lead ECGs, to assess the performance of ACE score for detection of Clinically Significant Portal Hypertension, using 6-lead and 12-lead ECG, and to assess and validate the performance of DULCE and ACE scores in 6-lead ECGs compared to 12-lead ECGs.

 

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Subjects over the age of 18 years.
  • Ability of subject to provide written, informed consent.
  • Patients with Chronic Liver Disease undergoing Transient Elastography (Fibroscan).

Exclusion Criteria:

  • Individuals under the age of 18.

Eligibility last updated 1/12/23. Questions regarding updates should be directed to the study team contact.

 

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Douglas Simonetto, M.D.

Open for enrollment

Contact information:

Amy Olofson R.N.

(507) 538-6547

Olofson.Amy@mayo.edu

More information

Publications

Publications are currently not available